Investing.com -- Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.
The company posted a loss per share of $0.13, significantly worse than the earnings per share (EPS) of $0.03 that analysts expected.
Revenue came in at $1.02 billion, also below the consensus estimate of $1.06 billion.
“Our first quarter fiscal 2025 results reflect the continued momentum in our business and underscore our customers’ continued confidence in Catalent. Financial highlights in the quarter included double-digit year-over-year growth in both non-COVID revenue and adjusted EBITDA, while also delivering positive free cash flow,” said Alessandro Maselli, President and CEO of Catalent.
In its Biologics segment, Catalent saw net revenue rise 3.1% year-over-year to $461 million, though this figure lagged behind the expected $476.2 million.
Meanwhile, Pharmaceuticals&Consumer Health achieved $563 million in net revenue, marking a 5.2% year-over-year increase, and also slightly under the forecast of $563.9 million.
Catalent’s adjusted EBITDA reached $125 million, representing an 8.7% year-over-year gain, but significantly short of the $164.8 million analysts anticipated.
Related Articles
Catalent reports Q1 loss, misses market expectations
R1 RCM reports mixed Q3 results, revenue beats estimates
Factbox-Airlines suspend flights as Middle East tensions rise
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。